RBC Capital Downgrades Immunogen Inc. (IMGN) to Sector Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Immunogen's (IMGN) Price Target Reduced to $5 at Morgan Stanley
May 2, 2016 9:49 AM EDTMorgan Stanley maintained an Underweight rating on Immunogen Inc. (NASDAQ: IMGN) and lowered its price target to $5.00 (from $9.00).
For an analyst ratings summary and ratings history on Immunogen Inc. click here. For more ratings news on Immunogen Inc. click here.
Shares of Immunogen Inc. closed at $6.85 yesterday.
... MoreUPDATE: RBC Capital Cuts Immunogen Inc. (IMGN) to 'Sector Perform' on Concerns About Lead Asset
April 29, 2016 2:28 PM EDT(Updated - April 29, 2016 2:44 PM EDT)
RBC Capital downgraded Immunogen Inc. (NASDAQ: IMGN) from Outperform to Sector Perform with a price target of $7.00 (from $18.00). Analyst Simos Simeonidis didn't like what he heard on the company's conference call regarding lead asset mirvetuximab soravtansine.
"We are downgrading IMGN to Sector Perform (from Outperform) on the news that lead asset mirvetuximab soravtansine produced a... More
Immunogen (IMGN) Misses Q3 EPS by 5c
April 29, 2016 8:33 AM EDTImmunogen (NASDAQ: IMGN) reported Q3 EPS of ($0.37), $0.05 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $19.7 million versus the consensus estimate of $23.02 million.
For earnings history and earnings-related data on Immunogen (IMGN) click here.
... More